Girard Partners’s Edwards Lifesciences EW Stock Holding History

Girard Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,680	Closed	-$97K	–	409
2018 Q3	$97K	Buy	+1,680	New	+$82.2K	0.02%	331

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Girard Partners's EW Position: Q4 2018 in Review

Girard Partners sold out of Edwards Lifesciences (EW) in Q4 2018, closing a stake of 1,680 shares — an estimated $97K sold.

Girard Partners first reported a position in EW in Q3 2018 and held it in 1 quarter. The position peaked at $97K in Q3 2018. 874 funds tracked by Wall St. Rank hold EW as of Q4 2018.

Girard Partners reported no remaining Edwards Lifesciences position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 1,680 Edwards Lifesciences shares in Q4 2018, an estimated $97K.
Girard Partners first reported a position in Edwards Lifesciences in Q3 2018 and held it in 1 quarter.
Girard Partners's Edwards Lifesciences position peaked at $97K in Q3 2018.
874 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.